PD-L1 immune suppression in cancer: Tumor cells or host cells?

Jan Willem Kleinovink, Thorbald van Hall, Ferry Ossendorp, Marieke F. Fransen

Research output: Contribution to journalArticleAcademicpeer-review


Four recent publications reported the role of PD-L1 expression on host versus malignant cells within the tumor for PD-1/PD-L1 checkpoint blockade therapy. All four research groups harmoniously report: PD-L1 expressed by both host as well as tumor cells are capable of suppressing T cell functions. Thus, checkpoint therapy can be effective, if malignant cells do not express PD-L1.
Original languageEnglish
Article numbere1325982
Issue number7
Publication statusPublished - 2017
Externally publishedYes

Cite this